Role of miR-195 in Chemo-Resistant Ovarian Cancer

miR-195 在化疗耐药性卵巢癌中的作用

• 批准号: 10640540
• 负责人: Shailendra Kumar Dhar Dwivedi
• 金额: $ 16.95万
• 依托单位: UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-05-01 至 2023-08-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10640540
• 关键词: 3' Untranslated Regions; 3-Dimensional; Adopted; Animal Model; Antineoplastic Agents; Binding Sites; Biological Assay; Calcium; Cancer Model; Cancer Patient; Carboplatin; Cells; Cellular Spheroids; Chemoresistance; Cisplatin; Data; Down-Regulation; Drug resistance; Ectopic Expression; Endothelial Cells; Endowment; Evolution; Fibroblasts; Formulation; Growth; Homing; Human; Immunofluorescence Immunologic; Implant; In Situ Nick-End Labeling; Invaded; Ligands; Luciferases; Maintenance; Malignant Conversion; Malignant Female Reproductive System Neoplasm; Malignant Neoplasms; Malignant neoplasm of ovary; Measures; Mediating; MicroRNAs; Mitochondria; Modeling; Molecular; Mus; Mutate; Neoplasm Metastasis; Ovary; PECAM1 gene; Paclitaxel; Pathway interactions; Patients; Pharmaceutical Preparations; Phenotype; Prognosis; Property; Proteins; Publishing; Recurrence; Recurrent Malignant Neoplasm; Reporting; Resistance; Role; Sampling; Scheme; Serous; Signal Pathway; Signal Transduction; Small Interfering RNA; System; Techniques; Testing; Therapeutic; Time; Tissue Microarray; Toxic effect; Transfection; Treatment Failure; Tumor Volume; Up-Regulation; WNT7A gene; Western Blotting; Xenograft Model; beta catenin; cancer cell; cancer drug resistance; cancer recurrence; cancer stem cell; cancer therapy; drug sensitivity; in silico; in vivo; migration; mortality; mouse model; novel; overexpression; patient response; stem; therapy outcome; therapy resistant; translatable strategy; tumor; tumor growth; tumor progression; uptake

Abstract Recurrence with drug resistance phenotype is frequent in high-grade serous ovarian cancer (HGSOC), the deadliest among gynecologic malignancies. However, molecular machineries responsible for recurrence and resistant phenotype in HGSOC are still evolving and urgently needed to overcome the therapeutic resistance and poor prognosis. In this context, establishing microRNA-195 (miR-195) as a critical molecule regulating drug resistance in HGSOC is significant. We recently reported that miR‐195 is under‐expressed in HGSOC, targets MICU1, and that its ectopic expression significantly reduces the clonal growth, migration, and invasion of ovarian cancer cells. Using a mouse model of ovarian cancer, we reported that miR-195 re-expression significantly reduces tumor growth, increases tumor doubling times, and enhances the overall survival of the tumor-bearing mouse. However, the role of miR-195 in drug resistance of HGSOC has not been elucidated. Interestingly, our in-silico analyses reveal that miR-195 can target WNT7A, a key ligand for the Wnt/β-catenin singling, which is upregulated in HGSOC and not detected in normal ovaries. Wnt/β-catenin singling in ovarian cancer is associated with stem-like properties in cancer cells with drug-resistant phenotype. Furthermore, we demonstrate in our preliminary data that miR-195 negatively regulates in Wnt/β-catenin signaling pathway in HGSOC cells. Based on these results, we hypothesize that the under-expression of miR-195 in HGSOC is responsible for WNT7A upregulation and evolution of the drug resistance phenotype. We will use specific aims below to test the hypothesis and accomplish overall objectives; Aim 1: Investigating the role of miR-195 expression in drug-resistant ovarian cancer. Aim 2: Evaluate the effect of miR-195 on metastasis and drug sensitivity in an ovarian cancer model using auroliposome mediated miR-195 delivery system. Successful completion of the project will establish miR-195 as a regulator of drug resistance in HGSOC and a potentially translatable strategy to overcome it either by miR-195 delivery or by targeting the WNT7A to inhibit the WNT/β- catenin pathway.

摘要